Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

This study is looking at how a cellular process called autophagy (where cells clean up and recycle their own damaged parts) is affected in HIV-infected patients on antiretroviral therapy. Specifically, it focuses on a gene called GALIG, which may play a role in how immune cells survive or die. The goal is to better understand why some HIV patients have poor immune recovery even when their virus is suppressed. **You may be eligible if...** - You are 18 or older - You are infected with HIV-1 (not HIV-2) - You are followed at Orleans' Regional Hospital - You fall into one of several study groups: on long-term suppressive therapy started during chronic infection (with either low or high CD4 counts), on therapy started during early (primary) infection, or not yet on treatment **You may NOT be eligible if...** - You are co-infected with HIV-2 - You are not followed at the specified hospital - You have not provided written consent Talk to your doctor to see if this trial is right for you.